Genetic susceptibility for COVID-19–associated sudden cardiac death in African Americans

John R. Giudicessi, MD, PhD,*† Dan M. Roden, MD,*‡§ Arthur A.M. Wilde, MD, PhD,*# Michael J. Ackerman, MD, PhD†**††

From the *Clinician-Investigator Training Program, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, †Division of Heart Rhythm Services, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, ‡Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, §Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, #Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, The Netherlands, **European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart), ***Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, and ††Department of Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota.

Introduction
Since emerging from Wuhan, China, in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), has infected >3.2 million individuals worldwide and ~1 million in the United States (as of April 29, 2020).1,2 Despite the institution of measures designed to “flatten the curve,” COVID-19 has claimed the lives of >225,000 individuals worldwide and >60,000 individuals in the United States alone (as of April 29, 2020).2 Of note, mortality estimates in some of the hardest hit regions have already or may need to be revised to account for a spike in sudden deaths occurring at home.3,4

Although most of these deaths are likely directly attributable to COVID-19 (eg, pulseless electrical activity/respiratory arrests), many of the same regions within the United States have also seen the outpatient prescription volume of COVID-19–directed heart rate–corrected QT interval (QTC)–prolonging drug(s), specifically hydroxychloroquine, rise by as much as 22,700% compared to the same time period (March 15–31) in 2019.7 Importantly, recent studies have shown that between 11% and 25% of hospitalized patients with COVID-19 treated with chloroquine or hydroxychloroquine and azithromycin had QTc values rise above the critical 500 ms threshold.6,7 As a result, a substantial number of patients with COVID-19, prescribed these so-called corona cocktails, may be at an increased risk of developing drug-induced long QT syndrome (DI-LQTS), which could deteriorate into drug-induced torsades de pointes (DI-TdP) or worse drug-induced sudden cardiac death (DI-SCD).8,9 Therefore, it stands to reason that the same phenomenon (DI-LQTS/DI-TdP) that has already halted 1 chloroquine/hydroxychloroquine clinical trial7 and led the Food and Drug Administration to caution against the use of chloroquine/hydroxychloroquine outside the hospital setting/clinical trial10 could also be contributing, at least in small part, to the increase in sudden deaths observed in some COVID-19 epicenters.

In addition, the COVID-19 pandemic has already highlighted alarming health disparities in the United States. For example, in Illinois where age, sex, and racial demographic data are reported for all COVID-19 cases, African Americans account for 26% of confirmed COVID-19 cases but 43% of COVID-19 deaths.11 A similar trend has been observed across the United States where COVID-19 mortality rates in predominantly black counties are 6-fold higher than that in predominantly white counties.12 Although this phenomenon is likely explained by the convergence of multiple cultural and socioeconomic factors,12 an underlying genetic susceptibility to SARS-CoV-2 infection, its
sequelae (such as hypoxia and inflammation), or the potentially lethal side effects of COVID-19–directed therapies (ie, DI-TdP and DI-SCD), assuming equal exposure to these medications, could also contribute.

Current evidence supports the notion that the common ion channel variants p.Asp85Asn-KCNE1 and p.Ser1103Tyr-SCN5A confer an increased risk of DI-LQTS and DI-SCD (Table 1). Importantly, p.Ser1103Tyr-SCN5A is seen almost exclusively in individuals of African descent and its frequency in that population (≈8%) is higher than that of p.Asp85Asn-KCNE1 (0.2%–2.5% depending on ancestry; 0.2% in individuals of African origin) (Table 1). Furthermore, unlike p.Asp85Asn-KCNE1 whose proarrhythmic potential is largely limited to DI-LQTS risk, the modest increase in late/persistent sodium current generated by p.Ser1103Tyr-SCN5A is accentuated markedly by hypoxia/acidosis and has been linked to an increased risk of ventricular arrhythmia (VA) and sudden cardiac death (SCD) in African Americans across the age spectrum.13–16

Given the potential of p.Ser1103Tyr-SCN5A to exacerbate outcome-related health disparities in the COVID-19 pandemic, this review was assembled to raise awareness of the multiple mechanism(s) whereby the proarrhythmic p.Ser1103Tyr-SCN5A common variant may increase the risk of VA/SCD in those of African descent as well as the importance of identifying modifiable risk factors for mortality during the COVID-19 pandemic.

Table 1 Epidemiological and functional data supporting a role for p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 in DI-LQTS risk

| Gene     | dbSNP ID         | Amino acid change | Overall MAF (gnomAD) | European MAF (gnomAD)* | Latino MAF (gnomAD) | African MAF (gnomAD) | SCN5A | rs7626962 | S1103Y | 0.008 0.08 | 0.0003 | 0.0003 | 0.01 | 0.003 | 0.0002 | 0.0009 | 0.0009 | 0.009 | 0.002 | 0.0002 |
|----------|------------------|-------------------|----------------------|------------------------|---------------------|--------------------|---------------------|--------|---------|--------|----------|--------|--------|------|--------|--------|--------|--------|--------|--------|--------|--------|
| SCN5A    | rs1805128        | D85N              | 0.009                | 0.000003               | 0.0003              | 0.01               | 0.0003             | 0.01   | 0.003   | 0.003  | 0.002    | 0.002  | 0.0002 |
| KCNE1    | rs1005128        | BS5N              | 0.009                | 0.0009                 | 0.0009              | 0.009              | 0.0009             | 0.009  | 0.0009  | 0.0009 |

| Electrophysiological phenotype (in vitro) | Odds ratio (95% confidence interval) | References |
|----------------------------------------|--------------------------------------|------------|
| Increased sustained/late INa secondary to altered inactivation gating that is accentuated by intracellular acidosis | 8.7 (3.2–23.9) | 16, 17 |
| Decreased IKs and/or IKr secondary to altered activation/inactivation kinetics | 9.0 (3.5–22.9) | 33 |

p.Ser1103Tyr-SCN5A and VA/SCD susceptibility in individuals of African descent

In individuals of African descent, the common SCN5A-encoded Na,1,5 sodium channel variant p.Ser1103Tyr-SCN5A has been associated with an increased risk of VA/SCD. Of note, this proarrhythmic potential has been reported to be enhanced by nongenetic risk factors known to reduce cardiac repolarization reserve (eg, hypokalemia and QTc-prolonging medication exposure; odds ratio 8.7; 95% confidence interval 3.2–23.9; $P = .00003$) and/or structural heart disease (relative risk 8.4; 95% confidence interval 2.1–28.6; $P = .001$) (Table 1). Furthermore, p.Ser1103Tyr-SCN5A was associated with potentiation of the QT-prolonging effect of hypokalemia in the 4476 participants of the Jackson Heart Study, suggesting that p.Ser1103Tyr-SCN5A contributes to decreased cardiac repolarization reserve at a population-specific level.

In addition, 2 population-based studies reported that p.Ser1103Tyr-SCN5A is overrepresented in African American sudden infant death syndrome decedents, providing additional epidemiological evidence that p.Ser1103Tyr-SCN5A confers an increased risk of sudden death in African Americans regardless of age.

Besides this epidemiological evidence, in vitro functional characterization by 2 independent groups demonstrated that p.Ser1103Tyr-SCN5A alters the inactivation gating of the Na,1,5 sodium channel (negative shift in the voltage dependence of steady-state inactivation [$V_{1/2}$]) and accentuates the sustained/late sodium current that is also the signature of the
electrophysiological phenotype displayed by the type 3 long QT syndrome (LQT3) pathogenic variants.\textsuperscript{16,17,20} That said, the experimental conditions—physiological pH vs low intracellular pH—under which p.Ser1103Tyr-SCN5A increased the late sodium current differed in the studies of Splawski et al\textsuperscript{17} and Plant et al,\textsuperscript{16} respectively. Furthermore, neither study demonstrated an in vitro or in silico ability of p.Ser1103Tyr-SCN5A to prolong the action potential duration (APD) in the absence of a "second hit" such as blockade of the rapid component of the delayed rectifier potassium current or intracellular acidosis. This appears to be consistent with (1) the exaggerated QTc response to hypokalemia observed in p.Ser1103Tyr-SCN5A–positive participants of the Jackson Heart Study\textsuperscript{18} and (2) a circumstance-dependent proarrhythmic state in infants (respiratory acidosis caused by hypoxia/apnea)\textsuperscript{16,19} and older (DI-LQTS in the setting of ≥1 QTc-prolonging drug and advanced structural heart disease) p.Ser1103Tyr-SCN5A–positive African Americans.\textsuperscript{14–16}

**Implications of p.Ser1103Tyr-SCN5A during the COVID-19 pandemic**

Direct and/or indirect myocardial injury/stress, as assessed by cardiac biomarkers such as troponin I and brain-type

**Table 2** COVID-19–directed pharmacotherapies with DI-TdP/DI-SCD risk

| Possible COVID-19 therapy | In vitro inhibition of SARS-CoV-2 | CredibleMeds classification | VT/VF/TdP/LQTS in FAERS\textsuperscript{*} | Cardiac arrest in FAERS\textsuperscript{*} | References |
|--------------------------|-----------------------------------|-------------------------------|---------------------------------------------|---------------------------------------------|------------|
| Repurposed antimalarial agents | Chloroquine | Yes | Known TdP risk | 72 | 54 | 34–36 |
|                           | Hydroxychloroquine | Yes | Known TdP risk | 222 | 105 | 37,38 |
| Repurposed antiviral agents | Lopinavir/ritonavir | Unknown\textsuperscript{1} | Possible TdP risk | 27 | 48 | 39–41 |
| Adjunct agents | Azithromycin | Unknown | Known TdP risk | 396 | 251 | 42,43 |

\textsuperscript{*}Adverse event reporting from postmarketing surveillance does not account for prescription volume and is often subjected to significant bias from confounding variables, quality of reported data, duplication, and underreporting of events.

\textsuperscript{1}Lopinavir/ritonavir inhibits other SARS viruses in vitro. However, a recent randomized trial demonstrated no benefit in COVID-19.
natriuretic peptide, has emerged as both a prominent and a prognostic feature in COVID-19. Of note, in an adjusted Cox regression model, the mortality risk associated with elevated cardiac biomarkers/acute cardiac injury was more significant than age and high-risk comorbid conditions such as chronic obstructive/pulmonary disease, diabetes, and a history of cardiovascular disease.

In addition, life-threatening VAs (eg, ventricular tachycardia/ventricular fibrillation) have been documented in 6% of hospitalized patients with COVID-19 and appear to be driven by underlying myocardial injury. The proposed mechanisms of acute myocardial injury and resulting VA risk in patients with COVID-19 include (1) direct SARS-CoV-2 myocardial infection (eg, myocarditis), (2) myocardial stress induced by hypoxemic respiratory failure, and/or (3) an exaggerated immune response that results in high levels of circulating cytokines (ie, interleukin-6 [IL-6], tumor necrosis factor-α, etc) directly injuring cardiomyocytes (Figure 1).

Notably, IL-6 may prolong the ventricular action potential via modulation of cardiac ion channel expression/function. Under normal physiological circumstances, Na1,5 cardiac sodium channels conduct a tiny amount of persistent/late sodium current that contributes minimally to the maintenance of the action potential plateau (ie ≤0.5% of the peak sodium current [INa]). However, in the setting of hypoxia, myocardial ischemia, heart failure, and LQT3-causative SCN5A gain-of-function variants, the relative contribution of the late sodium current can increase up to 10-fold to 4%-5% of the peak INa. In turn, this “pathological” late sodium current can prolong ventricular APD and predispose to VA/SCD.

As discussed previously, p.Ser1103Tyr-SCN5A Na1,5 sodium channels function normally under physiological conditions (eg, intracellular pH of 6.9–7.1). However, when intracellular pH is decreased in vitro to levels consistent with respiratory acidosis that occurs secondary to hypoxia/prolonged apnea (eg, intracellular pH of 6.6–6.8), p.Ser1103Tyr-SCN5A Na1,5 sodium channels generate a proarrhythmic, LQT3-like increase in persistent/late sodium current (~5% of the peak INa). This mechanism was put forward initially to explain the gene-environment interaction(s) responsible for the association between p.Ser1103Tyr-SCN5A and sudden infant death syndrome. However, the profound hypoxia observed in many COVID-19 cases raises reasonable concern that p.Ser1103Tyr-SCN5A could produce a similar African American–specific susceptibility to hypoxia-induced VA/SCD in the setting of SARS-CoV-2 infection/COVID-19 (Figure 1).
Unfortunately, the increased risk of VA/SCD linked to the potentially proarrhythmic p.Ser1103Tyr-SCN5A common variant is likely not limited to the possibility of hypoxia-induced VA/SCD. As succinctly outlined in recent work by Lazzerini et al.,27 the exaggerated immune response triggered by SARS-CoV-2 infection, specifically elevation of IL-6, likely increases arrhythmia risk via (1) modulation of cardiac ion channel expression/function leading to APD prolongation (eg, direct IL-6-mediated blockade of hERG/K, 11.1 potassium channels), (2) cardiac sympathetic nervous system hyperactivity, and (3) inhibition of cytochrome P450 enzymes involved in the metabolism of some QTc-prolonging drugs (eg, IL-6 and CYP3A4) (Figure 1). The latter effect of IL-6 is particularly important given that a number of COVID-19 pharmacotherapies (eg, hydroxychloroquine ± azithromycin and lopinavir/ritonavir) under investigation and/or in use clinically are known to prolong the QTc interval and predispose to DI-TdP/DI-SCD (Table 2).8,30

Taken together, these data suggest that 1 in 13 African Americans may be at a substantially increased risk of potentially lethal VAs, most notably DI-TdP, during the COVID-19 pandemic because of the perfect storm of (1) intrinsic genetic susceptibility (ie, p.Ser1103Tyr-SCN5A), (2) modifiable environmental risk factors (eg, electrolyte abnormalities and concurrent QTc-prolonging drug use), and (3) COVID-19–specific risk factors (eg, profound hypoxemia and cytokine storm) (Figure 1). Whether population-specific genetic risk factors such as p.Ser1103Tyr-SCN5A are contributing to the spike in sudden deaths and racial health disparities observed in COVID-19 epicenters remains to be proven, and given the lack of banked DNA in these epicenters, this speculation may not even be testable.

Nevertheless, given the potential for COVID-19 to exacerbate known gene-environment interactions pertaining to the potentially proarrhythmic p.Ser1103Tyr-SCN5A common variant, it seems reasonable (1) to avoid using COVID-19–directed QTc-prolonging drugs (eg, hydroxychloroquine ± azithromycin and lopinavir/ritonavir) unless careful, and preferably personal protective equipment–sparring, cardiac monitoring can be implemented (Figure 2)8,30; (2) to explore the association between p.Ser1103Tyr-SCN5A and rates of sudden death and COVID-19–related mortality in areas with medical record–linked DNA biobanks (eg, UK Biobank); (3) to investigate further the feasibility of point-of-care p.Ser1103Tyr-SCN5A genetic testing; and (4) to determine the clinical utility of QTc-shortening agents such as late sodium current blockers (eg, mexiletine and lidocaine) and anti-IL-6–targeted therapies (eg, tocilizumab and sarilumab)27,30 to better protect at-risk individuals, especially African Americans in the context of the ongoing COVID-19 pandemic.

Conclusion
A potentially pro-arrhythmic common variant, p.Ser1103Tyr-SCN5A, present in 1 out of 13 individuals of African descent has the potential to increase the risk of drug- and hypoxia-induced ventricular arrhythmias/sudden cardiac death and contribute to observed racial health disparities in the COVID-19 pandemic. As such, the use of unproven, QTc-prolonging COVID-19-directed therapies, most notably the combination of hydroxychloroquine and azithromycin, should be limited to settings where careful cardiac monitoring can be implemented (eg, hospital setting or clinical trial).

References
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020;20:533–534.
3. Deaths from cardiac arrests have surged in New York City. The Economist. https://www.economist.com/graphic-detail/2020/04/13/deaths-from-cardiac-arrests-have-surged-in-new-york-city. Published April 13, 2020. Accessed April 29, 2020.
4. Katz J, Lu D, Sanger-Katz M. US. Coronavirus death toll is far higher than reported, C.D.C. data suggests. The New York Times. https://www.nytimes.com/interactive/2020/04/26/us/coronavirus-death-toll-total.html. Published April 28, 2020. Accessed April 29, 2020.
5. Williams M. Hydroxychloroquine prescription volume changes during COVID-19. Swoop Web site. https://www.swoop.com/news/hydroxychloroquine-prescription-volume-changes-during-covid-19. Accessed April 26, 2019.
6. Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin [published online ahead of print April 24, 2020]. Nat Med. https://doi.org/10.1016/j.nmed.2020.05.014.
7. Brito MGS, Val FFA, Sampano VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 2020;3:e2008857.
8. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc 2020;95:1213–1221.
9. Wu C, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm 2020;17:1456–1462.
10. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting. Accessed April 26, 2020.
11. COVID-19 statistics. Illinois Department of Health Web site. https://www.dph. illinois.gov/covid19/covid19-statistics. Accessed April 29, 2020.
12. Yancy CW. COVID-19 and African Americans. JAMA 2020;323:1891–1892.
13. Giudicessi JR, Roden DM, Wilde AAM, Ackerman MJ. Classification and reporting of potentially proarrhythmic common genetic variation in long QT syndrome genetic testing. Circulation 2018;137:619–630.
14. Burke A, Creighton W, Mont E, et al. Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation 2005;112:798–802.
15. Sun AY, Koontz JI, Shah SH, et al. The S1103Y cardiac sodium channel variant is associated with implanted cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction. Circ Cardiovasc Genet 2011;4:163–168.
16. Plant LD, Bowers PN, Liu Q, et al. A common cardiac sodium channel variant associated with sudden infant death in African Americans. SCNSA S1103Y. J Clin Invest 2006;116:430–435.
17. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002;297:1333–1336.
18. Akylbekova EL, Payne JP, Newton-Cheh C, et al. Gene-environment interaction between SCN5A-S1103Y and hypokalemia influences QT interval prolongation in African Americans: the Jackson Heart Study. Am Heart J 2014;167:116–122.e11.
19. Van Norstrand DW, Tester DJ, Ackerman MJ. Overrepresentation of the proarrhythmic sudden death predisposing sodium channel polymorphism S1103Y in a population-based cohort of African-American sudden infant death syndrome. Heart Rhythm 2008;5:712–715.
20. Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995;376:683–685.
21. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069.
22. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062.

23. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802–810.

24. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:811–818.

25. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020;75:2352–2371.

26. Akhmerov A, Marban E. COVID-19 and the heart. Circ Res 2020;126:1443–1455.

27. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation 2020;142:7–9.

28. Makielski JC. Late sodium current: a mechanism for angina, heart failure, and arrhythmia. Trends Cardiovasc Med 2016;26:115–122.

29. Belardinelli L, Giles WR, Rajamani S, Karagueuzian HS, Shryock JC. Cardiac late Na(+) current: proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress. Heart Rhythm 2015;12:440–448.

30. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 treatment. Circulation 2020;141:e906–e907.

31. Giudicessi JR, Noseworthy PA, Ackerman MJ. The QT interval: an emerging vital sign for the precision medicine era? Circulation 2019;139:2711–2713.

32. Mitra RL, Greenstein SA, Epstein LM. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: possible benefits of intravenous lidocaine. HeartRhythm Case Rep 2020;6:244–248.

33. Kaab S, Crawford DC, Sinner MF, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 2012;5:91–99.

34. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–271.

35. Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W. Inhibition of hERG K+ currents by antimarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 2004;484:41–48.

36. Stas P, Faes D, Noyens P. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. Int J Cardiol 2008;127:e80–e82.

37. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxochloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732–739.

38. Chen CY, Wang FL, Lin CC. Chronic hydroxochloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 2006;44:173–175.

39. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004;31:69–75.

40. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787–1799.

41. Soliman EZ, Lundgren JD, Roediger MP, et al; INSIGHT SMART Study Group. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011;25:367–377.

42. Giudicessi JR, Ackerman MJ. Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused? Cleve Clin J Med 2013;80:539–544.

43. Arellano-Rodrigo E, Garcia A, Mont L, Roque M. Torsade de pointes and cardio-respiratory arrest induced by azithromycin in a patient with congenital long QT syndrome [in Spanish]. Med Clin (Barc) 2001;117:118–119.